# Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

> **NCT00004317** · PHASE4 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 600 (estimated)

## Conditions studied

- Toxoplasmosis

## Interventions

- **DRUG:** Leucovorin calcium
- **DRUG:** Pyrimethamine
- **DRUG:** Spiramycin
- **DRUG:** Sulfadiazine

## Key facts

- **NCT ID:** NCT00004317
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2000-07
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2009-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004317, "Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*